Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,132,000.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00. Following the completion of the sale, the chief operating officer now directly owns 606,525 shares of the company’s stock, valued at $6,865,863. This represents a 14.15 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Eric Venker also recently made the following trade(s):

• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.65, for a total value of $1,165,000.00.

Roivant Sciences Price Performance

ROIV stock opened at $12.53 on Monday. The business has a fifty day moving average price of $11.69 and a 200 day moving average price of $11.33. The stock has a market capitalization of $9.27 billion, a price-to-earnings ratio of 2.22 and a beta of 1.24. Roivant Sciences Ltd. has a fifty-two week low of $8.61 and a fifty-two week high of $13.06.

Analyst Ratings Changes

A number of research analysts recently issued reports on ROIV shares. Bank of America raised their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.93.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in Roivant Sciences in the second quarter worth about $34,000. Gladius Capital Management LP bought a new stake in shares of Roivant Sciences during the third quarter worth approximately $35,000. Point72 Hong Kong Ltd acquired a new stake in Roivant Sciences during the 2nd quarter worth $36,000. US Bancorp DE raised its position in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after acquiring an additional 1,948 shares during the last quarter. Finally, Quarry LP bought a new stake in shares of Roivant Sciences during the 2nd quarter valued at $53,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.